Moderna, Inc. (MRNA)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
Moderna will announce Q2 2024 earnings this Thursday, 1st August. Moderna stock hit highs of $450 per share in late 2021, but has since seen a decrease ~$120, and a current market cap valuation of ~$47bn. Revenue guidance for 2024 is for $4bn, although this is primarily dependent on the emergence of a significant private COVID-19 vaccination market, which is not guaranteed.
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
Why Moderna (MRNA) Dipped More Than Broader Market Today
The latest trading day saw Moderna (MRNA) settling at $121.25, representing a -1.02% change from its previous close.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Moderna co-founder Robert Langer to step down from vaccine maker's board
Robert Langer, co-founder and a key figure behind Moderna's scientific success, will step down from the vaccine maker's board on Aug. 5, the company said on Tuesday.
David Rubenstein Joins Moderna's Board of Directors
Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen Berenson Co-founder and director Robert Langer also to retire from the Moderna Board; recruitment efforts ongoing for his replacement CAMBRIDGE, MA / ACCESSWIRE / July 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that David M. Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group, will join Moderna's Board of Directors, effective August 5, 2024.
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
2 Growth Stocks Down 25% to Buy Right Now
Starbucks is struggling in the short term but has a clear path to improved results. Moderna can expect increased revenue after a new vaccine it developed received FDA approval.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Is Moderna Stock a Buy?
Moderna's performance slowed as the pandemic's worst effects began to wane. The company is notching important clinical and regulatory wins.
